Intraorbital corticosteroid injection for orbital reactive lymphoid hyperplasia.
OBJECTIVE
The purpose of this study is to assess the utility of intraorbital injection of triamcinolone acetonide as a primary treatment option for orbital reactive lymphoid hyperplasia (RLH).


METHODS
Retrospective, single-centre, interventional case series.


RESULTS
Intraorbital injection of triamcinolone acetonide was associated with complete resolution of all symptoms and signs in four cases (80%). This was achieved with a single injection in two cases and with two injections in another two cases. Radiological resolution was confirmed in one case. One case developed bilateral multifocal orbital RLH lesions 1 month after the second injection.


CONCLUSIONS
Intraorbital injection of corticosteroid may be a useful treatment option for orbital RLH, and may have a role as a first-line therapy in RLH of the anterior orbit. A significant proportion of patients may require repeat injections to achieve resolution. A larger prospective study is required to validate our findings.
South Australian Institute of Ophthalmology and the Department of Ophthalmology and Visual Sciences, University of Adelaide, Adelaide, South Australia. nick.h.andrew@gmail.com
N H
NH
Andrew
D
D
Kearney
D
D
Selva
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000328:Adult; D005260:Female; D006801:Humans; D056965:Injections, Intraocular; D008297:Male; D008875:Middle Aged; D009916:Orbital Diseases / Q000188:drug therapy*; D019310:Pseudolymphoma / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*
D000305:Adrenal Cortex Hormones; D014222:Triamcinolone Acetonide